Company Overview and News

 
Bursa Malaysia remains higher at mid-morning

2018-04-16 themalaymailonline
The Edit: Watch Han Solo and Chewie in this new ‘Solo: A Star Wars Story’ clip
Upvote Downvote

 
Genting plans to bid for Japan gaming licence

2018-04-09 thestar.com.my
PETALING JAYA: Genting Bhd is optimistic that the Japan Integrated Resort Execution Bill will be tabled in this year’s Diet session, paving the way for the group to formally bid for its Japan gaming licence.
Upvote Downvote

 
Mixed fortunes for billionaire owners as stocks struggle to hold gains

2018-03-09 thestar.com.my
KUALA LUMPUR: Billionaire bankers and palm oil planters continue to see their wealth grow year-to-date, as the share price of their flagship companies outperformed the broader stock market rise, fuelled by strong earnings outlook.
Upvote Downvote

 
Bursa ends lower as global sell-off continues

2018-03-02 themalaymailonline
KUALA LUMPUR, March 2 — Bursa Malaysia finished the week lower today, tracking the extended global sell-off as trade war worries emerged following US President’s hefty steel and aluminum import tariff decision.
Upvote Downvote

 
KL shares in red zone at mid-afternoon

2018-03-02 themalaymailonline
KUALA LUMPUR, March 2 — Shares on Bursa Malaysia remained in the red zone at mid-afternoon today, weighed down by selling in selected heavyweights led by Press Metal following US President Donald Trump's plan to impose steep tariffs on steel and aluminum imports.
Upvote Downvote

 
Genting, Genting Malaysia shares up on special dividend

2018-02-28 thestar.com.my
KUALA LUMPUR: Genting Bhd and Genting Malaysia Bhd shares rose in active trading on Wednesday after the announcing record high dividend.
Upvote Downvote

 
Trading ideas: Genting, Genting Malaysia, SunCon, Tropicana

2018-02-28 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Genting Bhd , Genting Malaysia Bhd , Sunway Construction Group Bhd and Tropicana Corp Bhd to be among the stocks to watch on Wednesday.
Upvote Downvote

 
Diary Malaysia 2018 corporate earnings

2018-02-19 thestar.com.my
KUALA LUMPUR: Following is a list of release dates for the quarterly earnings of some top Malaysia-listed companies.
Upvote Downvote

 
Harrowing week for equities, KLCI closes down nearly 20pts on Friday

2018-02-09 thestar.com.my
KUALA LUMPUR: Global equities markets had a harrowing week from the fallout on Wall Street and Bursa Malaysia also saw investor sentiment battered while the ringgit lost ground. At 5pm, the KLCI was down 19.62 points or 1.07% to 1,819.82 while its year-to-date gains have whittled to 1.28%. Turnover declined to 2.45 billion shares valued at RM2.67bil.  The broader market continued to stay cautious with decliners beating advancers nine to two or 900 losers to 208 gainers and 312 counters unchanged.
Upvote Downvote

 
Genting Malaysia’s near-term prospects uncertain due to higher costs, says CIMB Equities Research

2018-02-08 themalaymailonline
The logo of Genting Malaysia Berhad seen at Genting Highlands in Pahang December 17, 2013. — Reuters picKUALA LUMPUR, Feb 8 — CIMB Equities Research says it believes the near-term outlook of Genting Malaysia could be clouded by the higher costs as it maintains its FY17-19F earnings forecasts.
Upvote Downvote

 
Mixed views on market selldown

2018-02-07 thestar.com.my
Volatile market: A punter watching trading boards at a private stock market gallery in Kuala Lumpur. The FBM KLCI closed 24.23 points up yesterday after falling 40.62 points Tuesday. — AP
Upvote Downvote

 
Broad selling across Asian, European markets, KLCI dn 17 points

2018-02-05 thestar.com.my
KUALA LUPUR: Asian and Europeans equities markets fell on Monday as investment sentiment was impacted by higher US bond yields and worries the US Federal Reserve could hike interest rates. At 5pm, the FBM KLCI was down 17.41 points or 0.93% to 1,853.07 but off the early low of 1,845. Turnover was 2.66 billion shares valued at RM2.84bil. Decliners beat advancers more than five to one or 966 losers to 167 gainers and 290 stocks unchanged.
Upvote Downvote

1
Malaysia’s top 40 richest people

2018-02-03 thestar.com.my
LAST year was dotted by the return of higher commodity prices and better economic growth. The world’s economies on average are back in business as growth rates and trade have started to improve once again after some period of uncertainty caused by a cooling China economy and also the slump in global crude oil prices.
Upvote Downvote

 
South-east Asia mostly up, Singapore falls after four sessions of gains

2018-01-25 themalaymailonline
Vietnam stocks rise as much as 2.5 per cent to its highest since May 2007 after a two-day closure due to technical issues. — File picSINGAPORE, Jan 25 — Most South-east Asian stock markets rose today in line with broader Asia, while investors awaited US President Donald Trump's speech in Davos amid worries about global trade wars.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...